Royalty Report: Drugs, Drug Discovery, Autoimmune – Collection: 304790

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Drug Discovery
  • Autoimmune
  • Kidneys
  • Disease
  • Cancer
  • cardiac
  • Diagnostic
  • Molecular
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 304790

License Grant
Licensee of Sweden was granted (i) an exclusive license to certain patents and joint intellectual property developed with Licensor and (ii) a non-exclusive license to certain of Licensor know-how as necessary or useful to develop and commercialize Nefecon or other product candidates.
License Property
Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant. Nefecon is currently the only pharmaceutical candidate in development for IgAN that is intended to be disease-modifying. Nefecon targets the ileum, the distal region of the small intestine, which is the presumed origin of IgAN due to the ileum being the location of the highest concentration of the Peyer’s patches, which are responsible for the production of secretory immunoglobulin A, or IgA, antibodies. Nefecon has been granted orphan drug designation for the treatment of IgAN in the United States and the European Union.
Field of Use
The filed of use is for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN for which there is a high unmet medical need and there are no approved treatments. IgAN is a progressive, chronic disease that over time results in deterioration of kidney function in patients, many of whom end up at risk of developing end-stage renal disease, or ESRD, with the need for dialysis or kidney transplant.

IgA nephropathy (IgAN), also known as Berger's disease or synpharyngitic glomerulonephritis, is a disease of the kidney (or nephropathy) and the immune system; specifically it is a form of glomerulonephritis or an inflammation of the glomeruli of the kidney. Aggressive Berger's disease (a rarer form of the disease) can attack other major organs, such as the liver, skin and heart.

Licensee is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.  Licensee expects that Nefecon will be the first treatment on the market indicated for IgAN, and, that Nefecon can successfully treat IgAN patients, their kidney function will be preserved.

IPSCIO Record ID: 365047

License Grant
The parties partnered in a Study of Sparsentan where the Licensor is entitled to compensation upon NDA submission.
License Property
Sparsentan, an investigational product candidate for the treatment of IgA nephropathy (“IgAN”). The Protect Study met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating a greater than threefold reduction of proteinuria from baseline after 36 weeks of treatment,
Field of Use
Field of use is for the treatment of IgA nephropathy (“IgAN”).

IgA nephropathy, a rare, immune complex mediated chronic glomerular disease.

Glomerular diseases affect the filtering units of your kidney, the glomeruli. Symptoms include foamy urine, pink urine, high blood pressure and swelling in your face, hands, ankles or feet. Many diseases can cause glomerular disease. The leading cause is diabetic nephropathy.

IPSCIO Record ID: 269086

License Grant
This exclusive license agreement with Licensee is to commercialize fostamatinib in all indications, including chronic ITP, AIHA, and IgAN, in Europe and Turkey.  Licensee will receive exclusive rights to fostamatinib in human diseases, including chronic immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and IgA nephropathy (IgAN).
License Property
Fostamatinib refers to fostamatinib disodium hexahydrate which is an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment (product called TAVALISSE®)

The Licensor is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The pioneering research focuses on signaling pathways that are critical to disease mechanisms.

Field of Use
Fostamatinib is a medication for the treatment of chronic immune thrombocytopenia.

Adult chronic immune thrombocytopenic purpura (chronic ITP) is an autoimmune disorder in which patients produce antiplatelet autoantibodies and specialized white blood cells that destroy their blood platelets and, in some cases, damage their megakaryocytes (the cells that produce platelets in the bone marrow), causing a decrease in platelet production. This results in a low blood platelet count (thrombocytopenia) that may produce bruising or excessive bleeding.

IPSCIO Record ID: 329550

License Grant
The Canadian Licensor grants the Japanese Licensee an exclusive, transferable license, with the right to grant sublicenses, under the Licensor Technology, the Product Marks and Licensor’s interest in Joint Technology to
(i)    use, Develop, have Developed, Commercialize and conduct Medical Affairs for the Products in the Field in the Licensee Territory, and
(ii)    Package and have Packaged the Products for use in the Field in the Otsuka Territory.

This agreement includes an exclusive and non-exclusive grant back from Licensee to Licensor.

License Property
Licensor is a biopharmaceutical company, is developing its proprietary investigational drug known as Voclosporin, a proprietary calcineurin inhibitor.

Voclosporin is a novel, investigational, orally administered treatment developed to treat patients with LN, a chronic, progressive inflammation of the kidneys that is one of the most serious complications of the autoimmune disease systemic lupus erythematosus (SLE).

Field of Use
The Field means use of the Product for the treatment and prevention of any and all diseases, conditions and indications in humans.  Voclosporin is known for the treatment of Lupus Nephritis (LN).

Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). Also called lupus, SLE is an autoimmune disease. With lupus, the body's immune system targets its own body tissues. Lupus nephritis happens when lupus involves the kidneys.

IPSCIO Record ID: 307845

License Grant
Licensee licensed rights to tivozanib. Pursuant to the license agreement, Licensee obtained an exclusive, sublicensable license to develop, manufacture and commercialize tivozanib worldwide except for Asia and the Middle East, where Licensor retained the rights to tivozanib.
License Property
Tivozanib (FOTIVDA®) is a vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor.  Tivozanib, a potent, selective and long half-life inhibitor of all three vascular endothelial growth factor, or VEGF, receptors is designed to optimize VEGF blockade while minimizing off-target toxicities, resulting in demonstrated improved anti-tumor activity, as measured by progression-free survival, or PFS, overall response rate, or ORR, and duration of response, and tolerability, as measured by the need for significantly fewer dose reductions and interruptions due to adverse events, compared to a non-selective VEGFR TKI, sorafenib.

Licensor is a specialty pharmaceutical company engaged in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major western markets.

Field of Use
The field of use is for the treatment of adult patients with advanced renal cell carcinoma (RCC).  

Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine.

Licensee is a biopharmaceutical company developing and seeking to commercialize the pipeline of product candidates designed to provide a better life for patients with cancer.  Licensee is working to develop and commercialize tivozanib in North America as a treatment for RCC and hepatocellular carcinoma, or HCC, and is studying tivozanib in combination with immune checkpoint inhibitors for the treatment of RCC and HCC in phase 2 trials.

IPSCIO Record ID: 344577

License Grant
Sub-licensor grants to Sub-licensee of Japan an exclusive sublicense, with the right to further sublicense to its Affiliates, to develop, have developed, make, have made, use, have used, offer to sell, sell, have sold, and import and export the Product or the Compound in the Sublicense Territory and to make, manufacture, have made and have manufactured outside the Sublicense Territory under the Sub-licensor Know-How, and the Patent Rights for all Indications in the Field.
License Property
Sub-licensor acquired an exclusive license under the Patent Rights and Know-How to sublicense, develop, have developed, make, have made, use, have used, offer to sell, sell, have sold, import and export the Product in the Sublicense Territory for all Indications in the Field.

Compound means ferric citrate FeC6Hs01 • xH20.

Patent
Ferric Organic Compounds, uses thereof and methods of making same
Method for treating Renal Failure

Field of Use
Field means the field of nephrology.

Nephrologyis a specialty of adult internal medicine and pediatric medicine that concerns with study of the kidneys, specifically normal kidney function (renal physiology) and kidney disease (renal pathophysiology), the preservation of kidney health, and the treatment of kidney disease, from diet and medication to renal replacement therapy (dialysis and kidney transplantation).

Indication means any therapeutic application for a Product for the treatment of hyperphosphatemia in end-stage renal disease, and for all other indications covered by the Patent Rights.

Hyperphosphatemia is an electrolyte disorder in which there is an elevated level of phosphate in the blood. Most people have no symptoms while others develop calcium deposits in the soft tissue. Often there is also low calcium levels which can result in muscle spasms.

IPSCIO Record ID: 330753

License Grant
Licensor grants global rights, excluding Greater China, to develop, manufacture and commercialize ANG-3777.

Under the License, Licensor is responsible for executing a pre-specified clinical development plan designed to obtain regulatory approvals of ANG-3777 for DGF and CSA-AKI.

Licensee holds global exclusive rights to commercialize ANG-3777 for this indication, except in Greater China, where licensed development and commercialization rights are granted exclusively to another party.

License Property
Licensor is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases.

Licensor has ANG-3777 technology relating to acute organ injury, effective organ self-repair hindered by a naturally-occurring mismatch in timing of peak levels of HGF concentration relative to c-Met expression, an issue that could be addressed by augmenting the activity of HGF with our HGF mimetic during the time of maximal c-Met expression. ANG-3777 has demonstrated several similarities to HGF, including c-Met dependence and selective c-Met receptor activation, without acting on other growth factor receptors.

ANG-3777, an HGF Mimetic, is a small molecule designed to mimic the biological activity of HGF. HGF activates the c-Met receptor, which triggers a cascade of pathways with a central role in tissue repair and organ recovery that has been well established.

Field of Use
The field of use is all therapeutic, prophylactic and diagnostic uses for renal indications, including forms of AKI, acute kidney injury, and congestive heart failure (collectively, the Renal Indications).

ANG-3777 for CSA-AKI means for patients at risk for developing CSA-AKI. This indication is a frequent complication of cardiac surgery.

ANG-3777 for DGF means to improve kidney function and reduce the severity of DGF following deceased-donor kidney transplantation in patients showing evidence of early kidney dysfunction.

IPSCIO Record ID: 29157

License Grant
The Company announced that the Licensor decided not to exercise its option under the product development and commercialization Agreement between the Licensor and the Licensee to License XL784 for further development and commercialization. The Licensee announced in October 2007 that a phase 2 trial of XL784 did not meet its primary endpoint of reducing proteinuria compared with placebo in patients with proteinuria associated with diabetic nephropathy. As a result of the Licensor's decision, the Licensee has the right to develop and commercialize XL784 either independently or in collaboration with third parties, subject to royalty payments to on sales of any products incorporating the compound. The Company itself does not intend to invest further in the development of this drug, but will seek a partner with which to take the compound forward.
Field of Use
XL784 is a potent small molecule inhibitor of the ADAM-10 metalloprotease enzyme, which plays a role in blood vessel formation and cell proliferation that can cause renal fibrosis and impairment.  Diabetic nephropathy (nephropatia diabetica), also known as Kimmelstiel-Wilson syndrome and intercapillary glomerulonephritis, is a progressive kidney disease caused by angiopathy of capillaries in the kidney glomeruli. It is characterized by nephrotic syndrome and diffuse glomerulosclerosis. It is due to longstanding diabetes mellitus, and is a prime cause for dialysis in many Western countries.  Nephropathy means kidney disease or damage. Diabetic nephropathy is damage to your kidneys caused by diabetes. In severe cases it can lead to kidney failure.  The kidneys have many tiny blood vessels that filter waste from your blood. High blood sugar from diabetes can destroy these blood vessels. Over time, the kidney isn't able to do its job as well. Later it may stop working completely. This is called kidney failure.

IPSCIO Record ID: 256221

License Grant
Licensor grants the Licensee of Sweden
–   an exclusive, including with regard to Licensor and its Affiliates, right and license under the Licensed Technology and Licensors rights in the Joint Technology to Exploit the Licensed Compounds and Licensed Products solely for the purpose of Developing, Manufacturing and Commercializing Licensed Products in the Field and in the Territory.
–  an exclusive, including with regard to Licensor and its Affiliates, right and license under the Licensor Acquired Technology to Develop, Manufacture and Commercialize the Licensed Compounds and Licensed Products in the Field and in the Territory.
–  an exclusive, including with regard to Licensor and its Affiliates, right and license and right of reference in the Territory under Licensor s and its Affiliates rights, titles and interests in and to the Regulatory Approvals, to Develop, Manufacture and Commercialize the Licensed Compounds and Licensed Products in the Field and in the Territory.

This agreement contains a non-exclusive grant-back from Licensee to Licensor.

License Property
The Licensor has certain proprietary compounds known as NHE3 inhibitors for use in the treatment of human diseases and disorders, and has filed an Investigational New Drug application for one of such compounds, designated as RDX5791.

The Lead Licensed Compound means the NHE3 inhibitor designated as RDX5791, which is the subject of the IBS-C IND and the Cardio/Renal IND, and any metabolites, salts, esters, free acid forms, crystal forms, free base forms, pro-drug forms, racemates and all optically active forms thereof.

The patents include Patent Family I regarding Compounds and Methods for Inhibiting NHE-Mediated Antiport in the Treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders;Patent Family II regarding Methods For Diverting Sodium From Systemic Circulation;  Patent Family Ill regarding Compounds and Methods for Inhibiting NHE-Mediated Antiport in the Treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders (Indanes);  and, Patent Family IV regarding Compounds and Methods for Inhibiting NHE-Mediated Antiport in theTreatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders (Multimers).

NHE3 inhibitor programme includes the Phase 2-ready lead compound RDX5791, for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD). NHE3 is the sodium–hydrogen antiporter 3, a protein essential in the absorption of sodium in the intestines.

Field of Use
On this basis, the Parties plan to develop RDX5791 for use in ESRD and CKD in addition to IBS-C, and intend to evaluate possible development in other diseases that are a consequence of sodium and fluid overload.

End-Stage Renal Disease (ESRD) is a medical condition in which a person's kidneys cease functioning on a permanent basis leading to the need for a regular course of long-term dialysis or a kidney transplant to maintain life.
Chronic kidney disease (CKD) means your kidneys are damaged and can't filter blood the way they should. The main risk factors for developing kidney disease are diabetes, high blood pressure, heart disease, and a family history of kidney failure.
IBS-C is a type of IBS in which the abdominal discomfort or bloating happens with constipation. Generally, constipation is when stools don't pass often enough (less than three times per week).

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.